Vedolizumab is a humanized monoclonal antibody and one of the safest biologics for the treatment ofboth forms of inflammatory bowel disease(IBD)-Crohn’s disease and ulcerative colitis.It targets theα4β7 integrinand...Vedolizumab is a humanized monoclonal antibody and one of the safest biologics for the treatment ofboth forms of inflammatory bowel disease(IBD)-Crohn’s disease and ulcerative colitis.It targets theα4β7 integrinand blocks leukocyte trafficking to the gut.Regardless of its efficacy in many patients,non-response to vedolizumabtreatment poses a significant clinical challenge.In this review,we synthesize recent findings on genomic,transcriptomic,proteomic,and cellular biomarkers of vedolizumab response,emphasizing their roles in predicting therapeutic outcomesand understanding non-responsiveness.Key insights include the identification of epigenetic and transcriptomicsignatures,the involvement of Th17 and IL-6 signaling,and the role of baseline inflammatory markers like albumin.Discrepancies in findings highlight the complexity of biomarker discovery and underscore the need for standardized,multiparametric approaches to refine personalized treatment strategies.By bridging knowledge gaps in vedolizumabresponsiveness,this review aims to advance biomarker-driven decision-making and improve outcomes for patientswith IBD.展开更多
基金supported by the Slovenian Research and Innovation Agency(ARIS)—Young Researcher Program(contract no.104-04/TK–6811)Research Core Funding P3-0427.
文摘Vedolizumab is a humanized monoclonal antibody and one of the safest biologics for the treatment ofboth forms of inflammatory bowel disease(IBD)-Crohn’s disease and ulcerative colitis.It targets theα4β7 integrinand blocks leukocyte trafficking to the gut.Regardless of its efficacy in many patients,non-response to vedolizumabtreatment poses a significant clinical challenge.In this review,we synthesize recent findings on genomic,transcriptomic,proteomic,and cellular biomarkers of vedolizumab response,emphasizing their roles in predicting therapeutic outcomesand understanding non-responsiveness.Key insights include the identification of epigenetic and transcriptomicsignatures,the involvement of Th17 and IL-6 signaling,and the role of baseline inflammatory markers like albumin.Discrepancies in findings highlight the complexity of biomarker discovery and underscore the need for standardized,multiparametric approaches to refine personalized treatment strategies.By bridging knowledge gaps in vedolizumabresponsiveness,this review aims to advance biomarker-driven decision-making and improve outcomes for patientswith IBD.
